Results 81 to 90 of about 11,568,194 (143)

Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report

Journal of Alzheimer's Disease Reports
Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease. Although amyloid-related imaging abnormalities (ARIA) occur predominantly early in treatment, reports of hemorrhagic events during extended ...
Yugo Takahashi, Naoyuki Shiraishi, Akihiro Tsukahara, Yukari Matsuda, Takuya Nishina, Hiroo Yoshikawa, Takashi Uzu, Etsuro Mori   +7 more
doaj   +1 more source

A fibril-selective single-domain antibody targets pathogenic amyloid-β assemblies and protects human neurons

iScience
Summary: Alzheimer disease is characterized by extracellular amyloid-β deposition that contributes to neuronal dysfunction and degeneration. Although anti-amyloid-β antibodies reduce plaque burden, their use requires monitoring for amyloid-related ...
Matt A. Greenlee, Soukaina Amniouel, Isabel Rivera, Jessica Suh, Natalia J. Martinez, Anton Simeonov, Elizabeth Head, Robert Tycko, Wei Zheng, Bryan D. Fleming, Qi Zhang   +10 more
doaj   +1 more source

A Population-Based Ultra-Widefield Digital Image Grading Study for Age-Related Macular Degeneration-Like Lesions at the Peripheral Retina. [PDF]

, 2015
Our understanding of the relevance of peripheral retinal abnormalities to disease in general and in age-related macular degeneration (AMD) in particular is limited by the lack of detailed peripheral imaging studies.
Florea, D, Lengyel, I, Peto, T, Leung, I, Bird, AC, Csutak, A, Jonasson, F   +6 more
core  

Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice

Molecular Neurodegeneration
Anti-amyloid antibody treatment for Alzheimer’s disease is linked to Amyloid-Related Imaging Abnormalities (ARIA), including vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H), especially in ApoE ε4/4 carriers.
Praveen Bathini, Stephan Schilling, Jens-Ulrich Rahfeld, David M. Holtzman, Takaomi C. Saido, Cynthia A. Lemere   +5 more
doaj   +1 more source

Baseline plasma C1q and C3 as potential biomarkers for lecanemab efficacy and ARIA risk in early Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION The classical complement cascade has been implicated in amyloid beta (Aβ) clearance and in the pathogenesis of amyloid‐related imaging abnormalities (ARIA) during anti‐amyloid monoclonal antibody therapy.
Gihwan Byeon, Jung‐Won Lee, Suhyung Kim, Yoo Hyun Um, Sheng‐Min Wang, Seunggyun Ha, Sonya Youngju Park, Ilah Shin, Jinhee Jang, Chang Uk Lee, Hyun Kook Lim, Dong Woo Kang   +11 more
doaj   +1 more source

The Impact of Anti-Amyloid Immunotherapies on Stroke Care

Anti-amyloid immunotherapies have recently emerged as treatments for Alzheimer’s disease. While these therapies have demonstrated efficacy in clearing amyloid-β and slowing cognitive decline, they have also been associated with amyloid-related
Mariel G. Kozberg, Philippe A. Bilodeau, John R. Dickson   +2 more
core   +1 more source

Severe cerebral amyloid angiopathy related inflammation (CAA-ri) associated with vaccination: Case report and literature review

Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a rapid but reversible autoimmune encephalopathy where spontaneous autoantibody reaction against amyloid beta deposited in cerebral blood vessels produces characteristic neuroinflammatory ...
Lau, Kui Kai, Tang, Michael, Kim, Jane, Chan, Koon Ho   +3 more
core   +1 more source

β-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase [PDF]

, 2004
β-Amyloid (βA) peptide is strongly implicated in the neurodegeneration underlying Alzheimer's disease, but the mechanisms of neurotoxicity remain controversial. This study establishes a central role for oxidative stress by the activation of NADPH oxidase
Abramov, A.Y., Duchen, M.R., Canevari, L.   +2 more
core  

Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer's Disease. [PDF]

Dtsch Arztebl Int
Vöglein J, Levin J, Brendel M.
europepmc   +1 more source

Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal. [PDF]

Alzheimers Dement
Tonietto M, Silvestri E, Belder CRS, Barkhof F, Fox NC, Smith J, Klein G.   +6 more
europepmc   +1 more source